Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Methyl 4-(4-bromophenyl)-4-oxobutanoate, also known as ethyl 2-bromo-2-methylpropanoate, is a chemical compound with the molecular formula C11H11BrO3. It is a yellowish liquid with a fruity odor and belongs to the class of organic compounds known as alpha-keto esters. Methyl4-(4-bromophenyl)-4-oxobutanoate is commonly used as a reagent in organic synthesis and pharmaceutical research.

30913-86-1

Post Buying Request

30913-86-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

30913-86-1 Usage

Uses

Used in Pharmaceutical Research:
Methyl 4-(4-bromophenyl)-4-oxobutanoate is used as a reagent in pharmaceutical research for the preparation of various pharmaceutical products. Its unique chemical structure allows it to be a valuable component in the synthesis of new and existing drugs.
Used in Organic Synthesis:
In the field of organic synthesis, Methyl 4-(4-bromophenyl)-4-oxobutanoate is used as a reagent to facilitate the formation of complex organic molecules. Its versatility in reactions makes it a useful tool for chemists working on the development of new compounds.
Used in Industrial Applications:
Although not explicitly mentioned in the provided materials, Methyl 4-(4-bromophenyl)-4-oxobutanoate may also have applications in various industrial processes, such as the production of specialty chemicals, fragrances, or dyes, due to its fruity odor and chemical properties.
Safety Considerations:

Check Digit Verification of cas no

The CAS Registry Mumber 30913-86-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,0,9,1 and 3 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 30913-86:
(7*3)+(6*0)+(5*9)+(4*1)+(3*3)+(2*8)+(1*6)=101
101 % 10 = 1
So 30913-86-1 is a valid CAS Registry Number.

30913-86-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name Methyl 4-(4-bromophenyl)-4-oxobutanoate

1.2 Other means of identification

Product number -
Other names methyl 4-p-bromophenyl-4-oxobutanoate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:30913-86-1 SDS

30913-86-1Relevant articles and documents

One-Pot Sequential Photoredox Chemistry and Asymmetric Transfer Hydrogenation with a Single Catalyst

Zhang, Xiao,Qin, Jie,Huang, Xiaoqiang,Meggers, Eric

, p. 571 - 577 (2018)

A sequential process is reported, in which different photoredox reactions are placed in sequence with asymmetric transfer hydrogenations of aryl ketones to provide a diverse set of chiral alcohols with enantioselectivities of up to 99 % ee. The method relies on a single chiral-at-metal catalyst which is added at the beginning of the two step sequence and only a final purification of the reaction product is required.

Biocatalytic Asymmetric Reduction of γ-Keto Esters to Access Optically Active γ-Aryl-γ-butyrolactones

??d?o-Dobrowolska, Anna,Borowiecki, Pawe?,Heider, Johann,Kroutil, Wolfgang,Reiter, Tamara,Schühle, Karola,Szaleniec, Maciej,Tataruch, Mateusz,Telatycka, Natalia

, (2020/04/20)

An efficient stereoselective syntheses of a series of functionalized optically active γ-aryl-γ-butyrolactones is achieved by enzymatic asymmetric reduction of the corresponding sterically demanding γ-keto esters employing wild-type and recombinant alcohol dehydrogenases. The best stereoselectivities for the reduction via hydrogen transfer was obtained with two short chain dehydrogenases (SDRs) of complementary stereospecificity from Aromatoleum aromaticum, namely the Prelog-specific NADH-dependent (S)-1-phenylethanol dehydrogenase [(S)-PED] and the anti-Prelog-specific (R)-1-(4-hydroxyphenyl)-ethanol dehydrogenase [(R)-HPED], respectively.Biotransformations catalyzed by both enzymes, followed by TFA-catalyzed cyclization of the resulting γ-hydroxy esters, furnished the respective (S)- and (R)-configured products with exquisite optical purity (up to >99% ee). The synthetic value was demonstrated on preparative scale for the asymmetric bioreduction of the model compound, methyl 4-oxo-4-phenylbutanoate, affording optically pure (S)-γ-phenyl-γ-butyrolactone (>99% ee) in 67–74% isolated yield at 89–95% conversion depending on the applied scale. (Figure presented.).

Transition Metal-Free Alkyne-Aldehyde Reductive C?C Coupling trough Cascade Borylation/Olefin Isomerization

Khan, Imran,Luo, Zhibin,Xu, Yin,Xie, Jimin,Zhu, Weihua,Liu, Bin

, (2020/05/04)

A direct approach to γ-keto esters through cascade alkyne-aldehyde reductive C?C coupling of propargyl esters and aromatic aldehydes under transition-metal-free (TM-free) fashion was developed. Compared with multistep processes, this procedure provides a

Bcl-2 INHIBITORS

-

Paragraph 0790; 0791, (2019/11/19)

Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.

TBAI/TBHP-Promoted Generation of Malonyl Radicals: Oxidative Coupling with Styrenes Leads to γ-Keto Diesters

Chowdhury, Soumyadeep Roy,Hoque, Injamam Ul,Maity, Soumitra

, p. 2824 - 2828 (2018/09/20)

A metal-free protocol for oxidative coupling of malonic esters with styrenes to form γ-keto diesters has been developed. Key to the success of this process is the generation of malonyl radicals from unfunctionalized malonic esters under organo-catalysis conditions with TBAI and TBHP. This process tolerates both terminal and internal olefins with diverse malonic esters. It provides a new green metal-free alternative to traditional metal mediated process for generation of malonyl radicals and there by γ-keto diesters.

Organoselenium-catalyzed synthesis of oxygen- and nitrogen-containing heterocycles

Guo, Ruizhi,Huang, Jiachen,Huang, Haiyan,Zhao, Xiaodan

supporting information, p. 504 - 507 (2016/02/18)

A new and efficient approach for the synthesis of oxygen and nitrogen heterocycles by organoselenium catalysis has been developed. The exo-cyclization proceeded smoothly under mild conditions with good functional group tolerance and excellent regioselectivity. Mechanistic studies revealed that 1-fluoropyridinium triflate is key for oxidative cyclization.

Remote activation of the nucleophilicity of isatin

Zari, Sergei,Kudrjashova, Marina,Pehk, Tonis,Lopp, Margus,Kanger, Tonis

supporting information, p. 1740 - 1743 (2014/04/17)

The concept of the remote activation of reactivity was first applied in asymmetric organocatalysis. An isatin 3-phenylimine derivative acts as a donor in the thiourea catalyzed asymmetric addition to unsaturated 1,4-ketoesters, affording aza-Michael adducts in high enantiomeric purity and yield.

Design and synthesis of tri-substituted chiral pyrrolidin-2-one derivatives as CCR4 antagonists

Sun, Wei,Tian, Linjie,Qi, Hui,Jiang, Dan,Wang, Ying,Li, Song,Xiao, Junhai,Yang, Xiaohong

, p. 1144 - 1152 (2013/10/21)

A series of tri-substituted chiral pyrrolidin-2-one derivatives have been designed and synthesized as CC chemokine receptor 4 (CCR4) antagonists. The structure of CCR4 was built by homology modeling. Asymmetric synthesis was applied to synthesize the R,R configuration chiral pyrrolidin-2-one scaffold. The stereoisomeric configurations of the compounds were identified by 2D 1H-1H COSY spectroscopy and 1D NOESY spectroscopy. This method was more economical and convenient than traditional X-ray single crystal diffraction. In addition, the interactions between these compounds and the N-terminal extracellular tail of CCR4 were studied using capillary zone electrophoresis. The CCR4 chemotaxis inhibition effect was tested in CCR4-transfected HEK293 cells. Several compounds showed potent activities as CCR4 antagonists. Among these compounds, 1c is the most active one. Its apparent binding constant of CZE experiment result is (1.569±0.11)×10 5 L·mol-1, and its percentage inhibition of the HEK293/CCR4 cells migration with the concentration of 1 μmol·L -1 in DMSO is 59%. And compound 1f has slightly higher affinity to N-terminal of CCR4 according to its apparent binding constant than 1b because of the introduced ester linkage. Further studies on the mechanism of these compounds are in progress. The structure of CCR4 based on bovine rhodopsin was built through homology modeling. And six tri-substituted chiral pyrrolidin-2-one derivatives have been designed and synthesized as CCR4 antagonists. Several of these compounds show high inhibitory effect in cell assays and higher affinity for the N-terminal of CCR4. Among the compounds, 1c exhibited excellent activity. Copyright

Cross metathesis of allyl alcohols: How to suppress and how to promote double bond isomerization

Schmidt, Bernd,Hauke, Sylvia

, p. 4194 - 4206 (2013/07/05)

Under standard conditions the cross metathesis of allyl alcohols and methyl acrylate is accompanied by the formation of ketones, resulting from uncontrolled and undesired double bond isomerization. By conducting the CM in the presence of phenol, the catalyst loading and the reaction time required for quantiative conversion can be reduced, and isomerization can be suppressed. On the other hand, consecutive isomerization can be deliberately promoted by evaporating excess methyl acrylate after completing cross metathesis and by adding a base or silane as chemical triggers.

NAPHTHALENE DERIVATIVE

-

Paragraph 0311, (2013/06/27)

The present invention provides compounds which can regulate VCP activity. The present invention provides the compound of formula (I) (R is as defined in the description) or oxides, esters, prodrugs, pharmaceutically acceptable salts or solvates thereof. The compounds can regulate VCP activity, and thus are useful for treating VCP-mediated diseases such as neurodegenerative diseases.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 30913-86-1